Comparison of Error Incidence Between Single-Tablet Versus Multiple-Tablet INSTI-Based Regimens in the Inpatient Setting.

IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Denise Kelley, Kayla Blackmon, Brian L Nguyen, Dusten T Rose
{"title":"Comparison of Error Incidence Between Single-Tablet Versus Multiple-Tablet INSTI-Based Regimens in the Inpatient Setting.","authors":"Denise Kelley, Kayla Blackmon, Brian L Nguyen, Dusten T Rose","doi":"10.1177/10600280251324337","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Errors related to antiretroviral therapy (ART) occur in up to 86% of hospitalized patients living with human immunodeficiency virus (HIV) and may contribute to treatment failure, drug resistance, adverse effects, and toxicity. ART can be administered as a single-tablet regimen (STR) or multiple-tablet regimen (MTR), with limited data on whether the number of tablets affects inpatient error incidence.</p><p><strong>Objective: </strong>The purpose of this study was to determine the error rate of substituting dolutegravir-based STRs to an MTR while admitted.</p><p><strong>Methods: </strong>This multicenter, retrospective, observational study in adult inpatients receiving ART for HIV evaluated continuation of bictegravir-based STR versus dolutegravir-based STR given as an MTR. The primary outcome was the composite error incidence when ART was dispensed as an STR versus MTR. Secondary endpoints included number of errors per patient encounter, between-group error types, time to error correction and pharmacist involvement, and conversion back to STR at discharge.</p><p><strong>Results: </strong>Of 514 patient encounters (257 bictegravir-based STR; 257 dolutegravir-based MTR), there was a significantly lower composite incidence of errors in the STR group versus the MTR group (23% vs 31.5%; <i>P</i> = 0.029). A significantly higher incidence of dose-related errors in the MTR group occurred related to renal or hepatic dose adjustments, which was the only significantly different between-group error type identified. Approximately one error per encounter was identified in both groups, with median time to error correction slightly over 1 day. Multiple-tablet regimens were converted back to an STR at discharge in 89.9% of admissions.</p><p><strong>Conclusion and relevance: </strong>Providing INSTI-based ART as an STR while admitted may reduce ART-related medication errors and has potential to improve patient care; however, use of an STR may not address errors related to inappropriate dosing in organ dysfunction. Increased vigilance for medication errors is warranted when substituting with MTRs in inpatient settings.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280251324337"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280251324337","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Errors related to antiretroviral therapy (ART) occur in up to 86% of hospitalized patients living with human immunodeficiency virus (HIV) and may contribute to treatment failure, drug resistance, adverse effects, and toxicity. ART can be administered as a single-tablet regimen (STR) or multiple-tablet regimen (MTR), with limited data on whether the number of tablets affects inpatient error incidence.

Objective: The purpose of this study was to determine the error rate of substituting dolutegravir-based STRs to an MTR while admitted.

Methods: This multicenter, retrospective, observational study in adult inpatients receiving ART for HIV evaluated continuation of bictegravir-based STR versus dolutegravir-based STR given as an MTR. The primary outcome was the composite error incidence when ART was dispensed as an STR versus MTR. Secondary endpoints included number of errors per patient encounter, between-group error types, time to error correction and pharmacist involvement, and conversion back to STR at discharge.

Results: Of 514 patient encounters (257 bictegravir-based STR; 257 dolutegravir-based MTR), there was a significantly lower composite incidence of errors in the STR group versus the MTR group (23% vs 31.5%; P = 0.029). A significantly higher incidence of dose-related errors in the MTR group occurred related to renal or hepatic dose adjustments, which was the only significantly different between-group error type identified. Approximately one error per encounter was identified in both groups, with median time to error correction slightly over 1 day. Multiple-tablet regimens were converted back to an STR at discharge in 89.9% of admissions.

Conclusion and relevance: Providing INSTI-based ART as an STR while admitted may reduce ART-related medication errors and has potential to improve patient care; however, use of an STR may not address errors related to inappropriate dosing in organ dysfunction. Increased vigilance for medication errors is warranted when substituting with MTRs in inpatient settings.

住院患者单片剂与多片剂胰岛素治疗方案的错误率比较。
背景:高达86%的人类免疫缺陷病毒(HIV)住院患者发生与抗逆转录病毒治疗(ART)相关的错误,可能导致治疗失败、耐药、不良反应和毒性。抗逆转录病毒治疗可分为单片方案(STR)或多片方案(MTR),关于片剂数量是否影响住院病人差错发生率的数据有限。目的:本研究的目的是确定入院时将基于重力的str替换为MTR的错误率。方法:这项多中心、回顾性、观察性研究对接受抗逆转录病毒治疗的成年住院患者进行了评估,以比替替韦为基础的抗逆转录病毒治疗与以多替替韦为基础的抗逆转录病毒治疗作为MTR。主要结果是ART作为STR与MTR的混合误差率。次要终点包括每个患者遇到的错误数量,组间错误类型,纠正错误的时间和药剂师参与,以及出院时转换回STR。结果:在514例患者中(257例双重力性STR;257例基于重力的MTR), STR组的综合错误率明显低于MTR组(23% vs 31.5%;P = 0.029)。MTR组中与肾脏或肝脏剂量调整相关的剂量相关错误发生率明显较高,这是确定的组间唯一显著不同的错误类型。在两组中,每次遇到大约一个错误,纠正错误的中位数时间略超过1天。89.9%的入院患者在出院时将多重片剂方案转换回STR。结论及相关性:入院时提供基于免疫系统的抗逆转录病毒治疗可减少与抗逆转录病毒治疗相关的药物错误,并有可能改善患者护理;然而,使用STR可能无法解决与器官功能障碍剂量不当相关的错误。当在住院环境中使用mtr替代时,应提高对用药错误的警惕。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
166
审稿时长
3-8 weeks
期刊介绍: Annals of Pharmacotherapy (AOP) is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 14 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信